Therapeutic regimens and factors associated with mortality in patients with severe COVID-19 infection treated at the Hospital Nacional Alberto Sabogal Sologuren, 2020

Authors

DOI:

https://doi.org/10.24265/horizmed.2021.v21n1.07

Keywords:

Coronavirus infections, Severe acute respiratory syndrome, Therapeutics, Adrenal cortex hormones, Mortality

Abstract

Objective: To explore the therapeutic regimen and factors associated with mortality in patients with severe COVID-19 infection treated at the Hospital Nacional Alberto Sabogal Sologuren in 2020. Materials and methods: An observational, case-control, analytical and prospective study conducted in patients with severe COVID-19 infection at hospital admission between June and September 2020. The study population was classified into two groups: case group (61 deceased patients) and control group (60 discharged patients). Data were analyzed using Stata statistical software. Bivariate and multivariate logistic regression analyses were performed with a 95 % confidence level. Results: As for patients with severe COVID-19 infection, ages older than 60 years are associated with mortality (p = 0.035; OR = 2.21; CI: [1.05 – 4.63]). Different therapeutic regimens were included in the research: patients who received high-dose methylprednisolone had more probability of dying compared to those who received other corticosteroids (p = 0.001; adjusted OR = 5.18; CI: [1.94 – 13.83]). Patients who were treated with azithromycin for more than five days had more probability of dying compared to those that took it for fewer days (p = 0.000; adjusted OR = 7.14; CI: [2.22 – 22.99]). The multivariate model showed a 73.06 % predictive probability of mortality for patients with severe COVID-19 infection. Conclusions: The therapeutic regimens that include the administration of high-dose methylprednisolone and azithromycin for more than five days increase the probability of dying in patients with severe COVID-19 infection. Furthermore, ages over 60 years were associated with mortality in the patients who participated in the study.

Downloads

Download data is not yet available.

References

Organización Mundial de la Salud. COVID-19: cronología de la actuación de la OMS [Internet]. 2020. Disponible en: https://www. who.int/es/news-room/detail/08-04-2020-who-timeline---covid-19

Organización Mundial de la Salud. Alocución de apertura del Director General de la OMS en la rueda de prensa sobre la COVID-19 celebrada el 11 de marzo de 2020 [Internet]. 2020. Disponible en: https://www. who.int/es/dg/speeches/detail/who-director-general-s-openingremarks-at-the-media-briefing-on-covid-19---11-march-2020

World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report-101 [Internet]. 2020. Disponible en: https:// www.who.int/docs/default-source/coronaviruse/situationreports/20200430-sitrep-101-covid-19.pdf?sfvrsn=2ba4e093_2

Ministerio de Salud. Covid 19 en el Perú - Sala Situacional COVID-19 Perú [Internet]. Lima; 2020. Disponible en: https://covid19.minsa. gob.pe/sala_situacional.asp

Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med. 2020; 201(11): 1380-8.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054-62.

Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci. 2020; 117(20): 10970-5.

Mahevas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv. 2020.

Ministerio de Salud. RM N° 240-2020-Minsa. Modificación del Documento Técnico: Prevención, Diagnóstico y Tratamiento de personas afectas por COVID-19 en el Perú [Internet]. Lima; 2020. Disponible en: http://sph-peru.org/wp-content/uploads/2020/05/ RM-240-2020-MINSA.PDF.pdf

Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020; 146(1): 110-8.

Ministerio de Salud. RM N° 139-2020-Minsa. Documento Técnico Prevención y atención de personas afectadas COVID-19 en el Perú [Internet]. Lima; 2020. Disponible en: https://cdn.www.gob.pe/ uploads/document/file/574295/resolucion-ministerial-139-2020- MINSA.PDF

Ministerio de Salud. RM N° 270-2020-Minsa. Modificación del Documento Técnico: Prevención, Diagnóstico y Tratamiento de personas afectas por COVID-19 en el Perú [Internet]. Lima; 2020. Disponible en: https://cdn.www.gob.pe/uploads/document/ file/694719/RM_270-2020-MINSA.PDF

Ministerio de Salud. RM N° 283-2020-Minsa. Modificación del Documento Técnico: Prevención, Diagnóstico y Tratamiento de personas afectas por COVID-19 en el Perú [Internet]. Lima; 2020. Disponible en: https://cdn.www.gob.pe/uploads/document/ file/710132/RM_283-2020-MINSA.PDF

Organización Mundial de la Salud. Corticosteroides for COVID-19. Living Guidance [Internet]. 2020. Disponible en: https://www.who. int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1

Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020; 56(6): 2002808.

Corral L, Bahamonde A, Revillas FA, Gomez-Barquero J, AbadiaOtero J, Garcia-Ibarbia C, et al. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. medRxiv. 2020.

Salton F, Confalonieri P, Meduri GU, Santus P, Harari S, Scala R, et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. Open Forum Infect Dis. 2020; 7(10): ofaa421.

Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifirò G. Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines. Drug Saf. 2020; 1-8.

Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020; 34: 101663.

Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020; 97: 396-403.

Zeng L, Xu P, Choonara I, Bo Z, Pan X, Li W, et al. Safety of azithromycin in pediatrics: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2020; 76(12): 1709-21.

Zaroff JG, Cheetham TC, Palmetto N, Almers L, Quesenberry C, Schneider J, et al. Association of azithromycin use with cardiovascular mortality. JAMA Netw Open. 2020; 3(6): 208199.

U. S. Food and Drug Administration. FDA Drug Safety Communication: Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms [Internet]. 2019. Disponible en: https://www.fda.gov/ drugs/drug-safety-and-availability/fda-drug-safety-communicationazithromycin-zithromax-or-zmax-and-risk-potentially-fatal-heart

Kalra RS, Tomar D, Meena AS, Kandimalla R. SARS-CoV-2, ACE2, and hydroxychloroquine: cardiovascular complications, therapeutics, and clinical readouts in the current settings. Pathogens. 2020; 9(7): 546.

Published

2021-03-30

How to Cite

1.
Llaro-Sánchez MK, Guzman-Ramos RN, Gamarra-Villegas BE, Campos-Correa KE. Therapeutic regimens and factors associated with mortality in patients with severe COVID-19 infection treated at the Hospital Nacional Alberto Sabogal Sologuren, 2020. Horiz Med [Internet]. 2021Mar.30 [cited 2025May2];21(1):e1346. Available from: https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/1346

Issue

Section

Original article